ADORA2A and plasma cell myeloma: The synergistic effect was observed when combining adenosine A2A receptor agonists with cAMP-hydrolyzing PDE inhibitors in multiple myeloma and diffuse large B cell lymphoma cell lines, as well as in primary patient samples (Rickles et al., 2010).